August

Cedarburg Pharmaceuticals (August 11, 2020)

Purisys, LLC (August 11, 2020)

National Center for Natural Products Research NIDA MPROJECT (August 11, 2020)

Mark D. Beale, M.D.; Decision and Order (August 11, 2020)

Cambrex High Point, Inc. (August 11, 2020)

Epic Pharma, LLC (August 11, 2020)

GE Healthcare (August 11, 2020)

Catalent CTS, LLC (August 11, 2020)

Tommy L. Louisville, M.D.; Decision and Order (August 10, 2020)

American Radiolabeled Chemicals, Inc (August 3, 2020)

Chattem Chemicals Inc (August 3, 2020)

Curium US LLC (August 3, 2020)

July

Proposed Rule: Reporting of Theft or Significant Loss of Controlled Substances (July 29, 2020)

Euticals Inc. (July 29, 2020)

Siegfried USA, LLC (July 29, 2020)

Salvatore Cavaliere, D.O.; Decision and Order (July 29, 2020)

Kaniz F. Khan-Jaffery, M.D.; Decision and Order (July 29, 2020)

Hamada Makarita, D.D.S.; Denial of Application (July 29, 2020)

AMPAC Fine Chemicals Virginia, LLC (July 28, 2020)

Frederick M. Silvers, M.D.; Decision and Order (July 28, 2020)

Frank Joseph Stirlacci, M.D.; Decision and Order (July 27, 2020)

Final Rule: Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants (PDF) (July 24, 2020)

Ampac Fine Chemicals LLC (July 24, 2020)

Arizona Department of Corrections (July 24, 2020)

United States Pharmacopeial Convention (July 17, 2020)

Cambrex Charles City (July 17, 2020)

Proposed Rule: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I (July 13, 2020)

Extension of Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I of the Controlled Substances Act (July 13, 2020)

Purisys, LLC (July 9, 2020)

Usona Institute (July 8, 2020)

Galephar Pharmaceutical Research, Inc. (July 8, 2020)

Xcelience (July 8, 2020)

Lipomed (July 7, 2020)

June

Organic Standards Solutions International, LLC (June 22, 2020)

Proposed Rule: Temporary Placement of Isotonitazene in Schedule I (June 18, 2020)

Cambrex Charles City (June 17, 2020)

Woodfield Distribution, LLC (June 17, 2020)

Order with Opportunity for Comment: Exempt Anabolic Steroid Products (June 15, 2020)

VHG Labs DBA LGC Standards (June 15, 2020)

SpecGx LLC (Correction) (June 11, 2020)

Cardinal Health (June 11, 2020)

Honeoye Manufacturing (June 9, 2020)

Research Triangle Institute (June 9, 2020)

Final Rule: Listing of Ethylone in Schedule I of Controlled Substances (June 8, 2020)

Sigma Aldrich Research Biochemicals, Inc. (June 5, 2020)

Chemtos, LLC (June 5, 2020)

Nalas Engineering Services, Inc. (June 5, 2020)

Catalent Pharma Solutions, LLC (June 4, 2020)

Akorn, Inc. (June 4, 2020)

Bellwyck Clinical Services (June 4, 2020)

60-Day Notice: Application for Permit To Import Controlled Substances for Domestic and/or Scientific Purposes; DEA Form 357 (June 3, 2020)

60-Day Notice: Report of Loss or Disappearance of Listed Chemicals and Regulated Transactions in Tableting/Encapsulating Machines; DEA Forms 107, 452 (June 3, 2020)

60-Day Notice: Import/Export Declaration for List I and List II Chemicals; DEA Forms 486, 486A (June 3, 2020)

60-Day Notice: Application for Permit To Export Controlled Substances; Application for Permit To Export Controlled Substances for Subsequent Reexport; DEA Forms 161, 161R, 161R-EEA (June 3, 2020)

60-Day Notice: Controlled Substances Import/Export Declaration; DEA Form 236 (June 3, 2020)

May

Agilent Technologies (May 29, 2020)

Rhodes Technologies (May 28, 2020)

Noramco, Inc. (May 22, 2020)

Biopharmaceutical Research Company LLC (May 19, 2020)

60-Day Notice: The National Forensic Laboratory Information System Collection of Analysis Data (May 18, 2020)

30-Day Notice: Revision of a Previously Approved Collection Report of Theft or Loss of Controlled Substance; DEA Form 106 (May 18, 2020)

SpecGx LLC (May 18, 2020)

Scientific Botanical Pharmaceutical, Inc. (May 18, 2020)

Proposed Rule: Placement of para-Methoxymethamphetamine (PMMA) in Schedule I (May 15, 2020)

Restek Corporation (May 15, 2020)

Proposed Rule: Placement of Zipeprol in Schedule I (May 14, 2020)

Isaac J. Hearne, M.D.; Decision and Order (May 7, 2020)

Purisys, LLC (May 7, 2020)

Novitium Pharma LLC (May 7, 2020)

Michael Thomas Watkins, M.D.; Decision and Order (May 7, 2020)

Almac Clinical Services Incorp. (ACSI) (May 7, 2020)

Alcami Wisconsin Corporation (May 7, 2020)

AndersonBrecon Inc. dba PCI of Illinois (May 7, 2020)

Research Triangle Institute (May 5, 2020)

Patheon API Manufacturing, Inc. (May 5, 2020)

Alcami Carolinas Corporation (May 5, 2020)

Unither Manufacturing LLC (May 5, 2020)

Absolute Standards, Inc. (May 5, 2020)

April

Kansky J. Delisma, M.D.; Decision and Order (April 29, 2020)

30-Day Notice: Contractor Drug Use Statement (April 28, 2020)

Malathy Sundaram, M.D.; Decision and Order (April 27, 2020)

Andersonbrecon, Inc, DBA PCI of Illinois (April 24, 2020)

Interim Final Rule; Reopening of Comment Period; Electronic Prescriptions for Controlled Substances (April 21, 2020)

Cedarburg Pharmaceuticals (April 21, 2020)

Sigma Aldrich Co., LLC (April 21, 2020)

United States Pharmacopeial Convention (April 20, 2020)

VHG Labs DBA LGC Standards (April 20, 2020)

Groff NA Hemplex LLC (April 20, 2020)

AMRI Rensselaer, Inc. (April 20, 2020)

Purisys, LLC (April 20, 2020)

Absolute Standards, Inc. (April 20, 2020)

AMRI Rensselaer, Inc. (April 20, 2020)

Lipomed (April 20, 2020)

Final Rule: Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance (April 17, 2020)

Denco, LLC (April 16, 2020)

Mylan Pharmaceuticals Inc. (April 16, 2020)

Final Rule: Designation of Benzylfentanyl and 4-Anilinopiperidine, Precursor Chemicals Used in the Illicit Manufacture of Fentanyl, as List I Chemicals (April 15, 2020)

Adjustments to Aggregate Production Quotas for Certain Schedule II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine and Pseudoephedrine for 2020, in Response to the Coronavirus Disease 2019 Public Health Emergency (April 10, 2020)

Temporary Placement of Fentanyl-Related Substances in Schedule I; Correction (April 10, 2020)

Interim Final Rule: Placement of Lemborexant in Schedule IV (April 7, 2020)

Proposed Rule: Placement of 4,4'-DMAR in Schedule I (April 7, 2020)

American Radiolabeled Chem (April 7, 2020)

Almac Clinical Services Incorp (ACSI) (April 7, 2020)

Benuvia Therapeutics Inc. (April 7, 2020)

Brewster Drug, Inc.; Decision and Order (April 3, 2020)

Gregory L. Molden, M.D.; Decision and Order (April 3, 2020)

Wildlife Laboratories, Inc. (April 1, 2020)

Shertech Laboratories, LLC (April 1, 2020)

March

Final Rule: Placement of FUB-AMB in Schedule I (March 30, 2020)

Pisgah Laboratories, Inc. (March 24, 2020)

Sharp (Bethlehem), LLC (March 24, 2020)

Cargill, Inc. (March 24, 2020)

Johnson Matthey Inc. (March 24, 2020)

Proposed Rule: Controls To Enhance the Cultivation of Marihuana for Research in the United States (PDF) (March 23, 2020)

John O. Dimowo, M.D.; Decision and Order (PDF) (March 19, 2020)

Siegfried USA, LLC (March 19, 2020)

Navinta LLC (March 19, 2020)

Proposed Rule: Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants (PDF) (March 16, 2020)

Interim Final Rule: Placement of Cenobamate in Schedule V (March 10, 2020)

Caligor Pharma Services (March 10, 2020)

SpecGx LLC (March 10, 2020)

Sigma Aldrich Research (March 10, 2020)

Siemens Healthcare Diagnostics Inc. (March 10, 2020)

William S. Husel, D.O.; Decision and Order (March 10, 2020)

Johnson Matthey Inc. (March 10, 2020)

S&B Pharma, Inc.; Correction (March 10, 2020)

Arizona Department of Corrections (March 10, 2020)